Ultrasound-Accelerated Catheter-Directed Thrombolysis for Acute XXXX .

@entity1 @entity1212 @entity548 @entity120 @entity1151 @entity1410 @entity67
PURPOSE: To evaluate the safety and efficacy of @entity1212 ( @entity1212 ) in @entity1 with submassive @entity1151 ( @entity1151 ). MATERIALS AND METHODS: This retrospective study comprised 45 consecutive @entity1 (15 prospective, 30 retrospective) who underwent @entity1212 for submassive @entity1151 from June 2012-May 2014. Inclusion criteria were @entity67 ( @entity67 ) as indicated by right ventricle-to-left ventricle (RV:LV) ratio > 0.9, symptoms of < 2 weeks' duration, and absence of absolute contraindication to thrombolysis. All @entity1 underwent pulmonary artery catheterization with a standardized protocol (24 mg recombinant tissue plasminogen activator). Hemodynamic evaluation immediately after @entity1212 , RV:LV ratio evaluation at 48-72 hours after @entity1212 by computed tomography angiography and echocardiography, and adverse event reporting for a minimum of 30 days were performed. Outcomes and complications are reported as per the Society of Interventional Radiology Reporting Standards for Endovascular Treatment of @entity1151 . RESULTS: @entity1212 was technically successful in 100% (n = 45) of @entity1 . Main pulmonary artery pressure significantly decreased from 49.8 mm Hg to 31.1 mm Hg (P < .0001). @entity67 significantly improved with mean RV:LV ratios decreasing from 1.59 to 0.93 (P < .0001). There were 6 complications: 4 minor @entity548 episodes at access sites and 2 major @entity548 complications (flank and arm @entity1410 ). All-cause mortality at 30 days was 0%. There were no readmissions for @entity1151 at 30 days after discharge. CONCLUSIONS: Ultrasound-accelerated catheter-directed thrombolysis using a standardized low-dose protocol is a safe and efficacious method of treatment of submassive @entity1151 to reduce @entity120 and @entity67 .
